Amae Health Closes $15M Series A

Amae Health, a San Francisco, CA-based company which specializes in delivering patient-centered care for people with severe mental illness, raised $15M in Series A funding.

The round was led by Quiet Capital with participation from Healthier Capital, Baszucki Group, Index Ventures Managing Partner Mike Volpi, and all of original seed investors – Bling Capital, 8VC, Virtue and Able Partners.

The company intends to us the funds to expand to new sites and invest in its precision medicine platform.

Led by CEO Stas Sokolin, and Chief Product Officer Sonia Garcia, Amae Health specializes in mental health care committed to improving the treatment and care of severe mental illnesses through a value-based, psychiatry-led model. By integrating comprehensive care teams and leveraging technology, the company aims to deliver enhanced outcomes for patients and create a new standard for mental health care.

Amae Health’s care model includes a phased approach to care, tailored to each patient’s needs, building a lifelong partnership with patients to manage their condition. The company is also going to be working on several research collaborations to advance the knowledge of treatment for severe mental illness, including an upcoming study with UCLA and Apple on Digital Sensing for SMI Patients. Amae Health is also working on a ketogenic study for the SMI population in collaboration with the Baszucki Group to further explore the benefits of metabolic psychiatry. The company also announced that they will leverage Palantir to develop a precision medicine platform to advance the field of psychiatry as a whole.

The inaugural clinic is based in Los Angeles.

Commenting on the news, Stas Sokolin said: “Severe mental illness is a chronic condition requiring lifelong, adaptive care. By focusing on the individual as a whole person and addressing their long-term needs, we create lasting change for our members. As a long-term care provider, we have built the infrastructure to be a research organization, driving the field of psychiatry forward. In the coming months, we will be launching several groundbreaking research trials to further advance the understanding and treatment of SMI.”